NEUROENDOCRINE TUMORS

This study is testing a targeted radiation treatment called Lu-DOTATATE for people with advanced neuroendocrine tumors that have continued to grow despite other treatments. The treatment uses a radioactive drug that seeks out and delivers radiation directly to tumor cells. Resear…

This study is testing whether a combination of two drugs, pembrolizumab and lenvatinib, can help control an aggressive form of prostate cancer that has spread. It is for men whose cancer has developed neuroendocrine features and has stopped responding to standard hormone therapie…

This study is testing whether combining two existing cancer drugs can help control advanced cancers that usually don't respond to standard immunotherapy. The trial is for adults with specific advanced cancers, like certain types of pancreatic, breast, and prostate cancer, who hav…

This is a very early safety study to find a safe dose of a new radioactive drug, [212Pb] VMT-alpha-NET, for people with advanced neuroendocrine tumors that have stopped responding to other treatments. The main goal is to see how much radiation the kidneys can safely handle during…

This study is testing a new combination treatment for people with advanced, high-grade neuroendocrine tumors (NETs) who have not yet received chemotherapy for their cancer that has spread. Up to 20 participants will receive an initial phase of chemotherapy plus an immunotherapy d…

This study compared a new radioactive drug treatment to standard therapy for people with advanced neuroendocrine tumors of the digestive system that had stopped responding to previous treatment. The trial involved 196 participants whose cancer had progressed despite standard care…

This study is comparing a newer, targeted radiation treatment called PRRT against the current best standard care for patients with aggressive neuroendocrine tumors in the digestive system or pancreas. It aims to see if the targeted therapy can better control tumor growth, improve…

This study is testing a drug called entrectinib for people with advanced solid tumors that have specific genetic changes (NTRK, ROS1, or ALK gene rearrangements). It's a 'basket trial,' meaning it groups patients by their tumor's genetic type rather than where the cancer started …

This study is testing whether a combination of two immunotherapy drugs (ipilimumab and nivolumab) can help control advanced rare cancers that have shown some sensitivity to these treatments before. It will involve 240 adults with specific rare cancers, including certain neuroendo…

This study is testing an experimental oral drug called CVM-1118 for people with advanced neuroendocrine tumors that have stopped responding to standard treatments. The main goal is to see if the drug can slow or stop the cancer from growing. Researchers will also closely monitor …

This study is testing whether combining two existing drugs—nivolumab (an immunotherapy) and temozolomide (a chemotherapy)—can help control cancers that have come back or stopped responding to standard treatments. It is for adults with recurrent small-cell lung cancer or advanced …

This study is collecting long-term safety information on Lutathera, a treatment already approved for advanced neuroendocrine tumors. Researchers are following 1,014 patients who have already received this treatment to monitor for rare or delayed side effects, particularly looking…

This study aims to create better rules for doctors to use when reading PET scans of patients with neuroendocrine tumors. Researchers will test if these new rules can more accurately predict whether a patient's cancer will get better, worse, or stay the same after treatment. They …

This study aims to improve how doctors use a special total-body PET scanner to see cancer more clearly. Researchers will test three different FDA-approved imaging agents in people with prostate cancer, breast cancer, or neuroendocrine tumors. The goal is to collect better data on…

This study aims to understand how different treatment sequences affect the quality of life and symptoms of people with neuroendocrine tumors (NETs). Researchers will follow over 2,500 patients for up to five years, linking their survey answers about their health and treatment exp…

This study aims to compare three different types of PET scans to see which works best for detecting metastatic neuroendocrine tumors. Researchers will scan 50 patients with this type of cancer to see if all scans show the same tumors or if some spots are missed. The goal is to ga…

This study follows patients for up to 15 years after they received experimental gene therapies for cancers like melanoma and neuroendocrine tumors. The goal is to monitor long-term safety and health outcomes, as required by the FDA. Participants will have regular check-ups, blood…